Title : Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.

Pub. Date : 2020 Jan

PMID : 31073076






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In a pre-clinical model of patient-derived TP53 mutant acute lymphoblastic leukemia, APR-246 reduced leukemia burden and strongly synergized with the genotoxic agent doxorubicin leading to superior leukemia-free survival in vivo. Doxorubicin tumor protein p53 Homo sapiens